January 7, 2009

OrthAlign Announces $7.2 Million Series A Financing Round

OrthAlign, Inc., a privately held medical device company in Orange County, CA, secured a $7.2 million Series A financing round led by Research Corporation Technologies (“RCT”) and Okapi Venture Capital, LLC. (“Okapi”). Additional participants include the company’s seed investors, D. Ronald Yagoda, and Ned Scheetz, along with CEO Pieter Wolters, and a group of accredited private individuals.

Christopher P. Martin, Senior Vice-President and CFO of RCT and Sharon Stevenson, DVM, PhD, Co-Founder and Managing Director at Okapi, have joined Ron Yagoda, Ned Scheetz and Pieter Wolters on OrthAlign’s Board of Directors.

“This round of financing provides us with the capital to finish developing our first line of products and bring them to market,” said Pieter Wolters, OrthAlign’s President and CEO. ”Initial prototypes have been received favorably by leading orthopedic surgeons. The company will have a booth at the American Academy of Orthopedic Surgeons in Las Vegas, NV, from February 25 through 28, 2009. We expect to have our first products available for clinical use in total knee replacement procedures in the second half of 2009”.

About OrthAlign, Inc.:

OrthAlign is developing a line of computer-assisted surgical devices that are affordable, hassle-free and easy to use. Through technology that provides the critical features and benefits of large surgical navigation systems in a disposable, palm-sized device, OrthAlign’s goal is to create a new standard of care in total joint replacement. For more information, visit www.orthalign.com.

About Research Corporation Technologies, Inc.:

Research Corporation Technologies in Tucson, AZ., is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT has assets of more than $300 million to advance technology development through venture investment, partnerships and special licensing programs. The RCT BioVentures program provides venture capital to companies whose technologies have the potential to become significant biomedical products. For more information, visit www.rctech.com.

About Okapi Venture Capital, LLC:

Founded in 2006, Okapi Venture Capital is a seed and early stage venture capital fund headquartered in Laguna Beach, CA. Okapi, with approximately $30 million dollars under management in its current fund, Okapi Ventures I, is focused on seed and early stage life sciences and information technology opportunities in Southern California. For more information, visit www.okapivc.com.